Login to Your Account



Clinic Roundup


Thursday, July 5, 2012
• Spectrum Pharmaceuticals Inc., of Henderson, Nev., said it started a Phase II trial of lucanthrone, an orally administered topoisomerase II and AP endonuclease inhibitor, as a primary therapy for glioblastoma multiforme.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription